Skip to main content
Sirona Biochem Corp. logo

Sirona Biochem Corp. — Investor Relations & Filings

Ticker · SRBCF ISIN · CA82967M1005 LEI · 549300CQE1Q87IG6W210 TSXV Real estate activities
Open in API
Filings indexed 367 across all filing types
Latest filing 2021-03-04 Regulatory Filings
Country CA Canada
Listing TSXV SRBCF

About Sirona Biochem Corp.

https://www.sironabiochem.com/

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery firm utilizing a proprietary platform technology to develop novel compounds. Through its wholly-owned French subsidiary, TFChem, the company specializes in stabilizing carbohydrate molecules, often via fluorination chemistry, to enhance their efficacy and safety for medical and cosmetic applications. Sirona Biochem's business strategy involves licensing or selling its patented compounds, such as the anti-aging and anti-wrinkle molecule GlycoProteMim™ (TFC-1326), to leading global pharmaceutical and cosmetic companies in exchange for up-front fees, milestone payments, and ongoing royalties.

Recent filings

Filing Released Lang Actions
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV1 Certification of Annual Filings by the CFO, certifying the review and fair presentation of the annual filings including the AIF, annual financial statements, and annual MD&A for the fiscal year ended October 31, 2020. The document is a certification letter, not the actual annual report or financial statements. It contains no substantive financial data or analysis itself, only an attestation. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the report they reference.
2021-03-04 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV1 Certification of Annual Filings by the CEO, certifying the review and fair presentation of the annual filings including the AIF, annual financial statements, and MD&A for the financial year ended October 31, 2020. It is primarily an officer certification letter and does not contain the actual financial statements or detailed report content. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than the actual Annual Report (10-K) or Management Reports (MDA). The document length is short (1356 characters), consistent with a certification letter rather than a full report.
2021-03-04 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings Classification · 100% confidence The document is a Form 13-501F1 related to participation fees for reporting issuers, including a management certification by an officer (CFO) certifying the accuracy of the information. It contains market value calculations for securities over specified trading periods and fee calculations. There are no financial statements, earnings data, or detailed management discussion. The document is primarily a regulatory form submission with officer certification to the Alberta Securities Commission. It does not fit into financial reports like Annual or Interim Reports, nor is it a call transcript or presentation. It is a regulatory filing with certification, so it falls under Regulatory Filings (RNS).
2021-03-04 English
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 100% confidence The document is titled 'Independent Auditor’s Report' and contains an auditor's opinion on the consolidated financial statements of Sirona Biochem Corp. for the years ended October 31, 2020 and 2019. It includes detailed audit procedures, basis for opinion, material uncertainty related to going concern, and responsibilities of management and auditors. The document also contains the consolidated financial statements themselves, including statements of financial position, loss and comprehensive loss, changes in shareholders' equity, and cash flows, with detailed notes and figures. The length is substantial (15,000 characters), and the content is the full audit report and financial statements, not merely an announcement or certification. Therefore, this document is a standalone Audit Report / Information filing, not an Annual Report or a simple announcement. The presence of the auditor's detailed opinion and the full financial statements confirms this classification. FY 2020
2021-03-04 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings Classification · 95% confidence The document is a Management Certification related to Form 13-502F1 for Class 1 and Class 3B Reporting Issuers, submitted to the Ontario Securities Commission. It includes detailed calculations of market value, participation fees, and references to OSC Rule 13-502 Fees. The document is primarily a certification by an officer (CFO) attesting to the accuracy and completeness of the information provided in the form. There are no financial statements or substantive financial data presented beyond fee calculations and market value summaries. The document is a regulatory filing related to fee reporting and certification rather than a full financial report or audit. Therefore, it fits best under Regulatory Filings (RNS) as it is a certification and submission to a regulatory body without detailed financial statements or management discussion.
2021-03-04 English
News release - English.pdf
Interim / Quarterly Report Classification · 90% confidence The document is titled 'Sirona Biochem CEO Quarterly Update Q1 2021' and provides a detailed update on various projects and progress made by the company during the first quarter of 2021. It includes substantive information about clinical trials, manufacturing, partnerships, and future plans. The content is more comprehensive than a brief earnings release and focuses on business progress and development rather than just financial results. It is not a transcript of a call, nor is it an announcement of a report publication. The document length (7,915 characters) supports it being a detailed update rather than a short announcement. Given these factors, the document fits best as an Interim / Quarterly Report (IR), which covers a period shorter than a full fiscal year and contains substantive business and financial progress information. Q1 2021
2021-02-24 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.